Endocrinol Metab.  2024 Aug;39(4):576-578. 10.3803/EnM.2024.401.

Levothyroxine Dosing for Thyroid-Stimulating Hormone Suppression in Patients with Differentiated Thyroid Cancer after Total Thyroidectomy

• Kim M

• KMID: 2558941
• DOI: http://doi.org/10.3803/EnM.2024.401

Reference

1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26:1–133.

2. Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab. 2008; 93:1167–9.

3. Diessl S, Holzberger B, Mader U, Grelle I, Smit JW, Buck AK, et al. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2012; 76:586–92.

4. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008; 93:809–14.

5. Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab. 2015; 100:3270–9.

6. Chen SS, Zaborek NA, Doubleday AR, Schaefer SC, Long KL, Pitt SC, et al. Optimizing levothyroxine dose adjustment after thyroidectomy with a decision tree. J Surg Res. 2019; 244:102–6.

7. Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid. 2010; 20:135–46.

8. Wang LY, Smith AW, Palmer FL, Tuttle RM, Mahrous A, Nixon IJ, et al. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid. 2015; 25:300–7.

9. Miccoli P, Materazzi G, Rossi L. Levothyroxine therapy in thyrodectomized patients. Front Endocrinol (Lausanne). 2021; 11:626268.

10. Tagay S, Herpertz S, Langkafel M, Erim Y, Freudenberg L, Schopper N, et al. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol. 2005; 153:755–63.

11. Lee JK, Ku EJ, Kim SJ, Kim W, Cho JW, Jung KY, et al. Effect of thyroid-stimulating hormone suppression on quality of life in thyroid lobectomy patients: interim analysis of a multicenter, randomized controlled trial in low- to intermediate-risk thyroid cancer patients (MASTER study). Ann Surg Treat Res. 2024; 106:19–30.

12. Ryu HJ, Choi MS, Park H, Kim TH, Chung JH, Park SY, et al. Adequate dose of levothyroxine for thyroid-stimulating hormone suppression after total thyroidectomy in patients with differentiated thyroid cancer. Endocrinol Metab (Seoul). 2024; 39:615–21.

13. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014; 24:1670–751.

14. Santini F, Pinchera A, Marsili A, Ceccarini G, Castagna MG, Valeriano R, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. 2005; 90:124–7.

15. Piers LS, Soares MJ, McCormack LM, O’Dea K. Is there evidence for an age-related reduction in metabolic rate? J Appl Physiol (1985). 1998; 85:2196–204.